Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire12-14

CAMBRIDGE, Mass., December 13, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491866645?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B6hBvhLcVr7UTLQTYTmJHA--~B/aD0yMDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f42f0efddf60555cc355858fcbb2253b","is_english":true,"pubTime":"2024-12-14 05:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491866645","market":"us","top_or_hot":-1,"title":"Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","media":"Business Wire","content":"<div>\n<p>CAMBRIDGE, Mass., December 13, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the \"Company\"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/scholar-rock-reports-employee-inducement-211500262.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-14 05:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/scholar-rock-reports-employee-inducement-211500262.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CAMBRIDGE, Mass., December 13, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the \"Company\"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/scholar-rock-reports-employee-inducement-211500262.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://finance.yahoo.com/news/scholar-rock-reports-employee-inducement-211500262.html","article_id":"2491866645","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B6hBvhLcVr7UTLQTYTmJHA--~B/aD0yMDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f42f0efddf60555cc355858fcbb2253b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491866645","pubTimestamp":1734124500,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CAMBRIDGE, Mass., December 13, 2024----Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 119,312 shares of common stock and inducement restricted stock units, covering an aggregate of 89,488 shares of its common stock.The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan  and the award agreements thereunder.Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy . This commitment to unlocking fundamentally different therapeutic approaches is p","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","PHH":"Park Ha Biological Technology Co. Ltd.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SRRK":"Scholar Rock Holding Corp","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","WRD":"文远知行","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC",".IXIC":"NASDAQ Composite","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Scholar Rock根据纳斯达克上市规则第5635(c)(4)条呈报新僱员奖励补助金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"NDAQ":1,"PHH":1,"WRD":1,"SRRK":0.9},"content_text":"CAMBRIDGE, Mass., December 13, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the \"Company\"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 119,312 shares of common stock and inducement restricted stock units, covering an aggregate of 89,488 shares of its common stock.\nThe awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the \"Plan\") and the award agreements thereunder.\nThe Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).\nThe inducement stock options have an exercise price of $45.48, which is equal to the closing price of Scholar Rock’s common stock on December 9, 2024. The inducement stock options will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of each employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 12 equal quarterly installments thereafter. Vesting for the inducement restricted stock units will be in four equal annual installments. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.\nAbout Scholar Rock\nScholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.\nScholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.\nScholar Rock® is a registered trademark of Scholar Rock, Inc.\nAvailability of Other Information About Scholar Rock\nInvestors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241213934828/en/\nContacts\nScholar Rock:InvestorsRushmie NofsingerScholar Rockrnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573MediaMolly MacLeodScholar Rockmmacleod@scholarrock.com media@scholarrock.com 802-579-5995","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491866645"}